ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 500

Can Thiol/Disulphide Is a Novel Marker in Rheumatoid Arthritis?

Sema Haliloglu1, cemile bicer2, Murat Alisik3, Bilge Ekinci4, Mehmet Emin Budak5, Omur volkan6, Hulya Uzkeser7 and Ayse Carlioglu8, 1Physical Medicine and Rehabilitation, Maltepe Occupational Diseases Hospital, Istanbul, Turkey, 2Biochemistry, Yildirim Beyazit University Medical Faculty, Ankara, Turkey, 3Biochemistry, Ataturk Training and Research Hospital, Ankara, Turkey, 4Physical Medicine and Rehabilitation, Erzurum Region Training and Research Hospital, Erzurum, Turkey, 5Endocrinology, Erzurum Region Training and Research Hospital, erzurum, Turkey, 6Rheumatology, Erzurum Region Training and Research Hospital, Erzurum, Turkey, 7Physical Medicine and Rehabilitation, Ataturk University,Medical Faculty, Erzurum, Turkey, 8Endocrinology, Erzurum Region Training and Research Hospital, Erzurum, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Diagnosis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Rheumatoid arthritis is a chronic, systemic, autoimmune disease about 5% -%1 of world population affected. Highly reactive oxygen free radicals are believed to be involved in the pathogenesis of the disease. Our aim was to investigate the thiol/disulphide homeostasis, which has an important role in many cellular activities such as antioxidant protection, detoxification, cell growth and apoptosis in patients with rheumatoid arthritis.

Methods:  Twenty female and five male patients diagnosed with RA according to American College of Rheumatology 1987 classification criteria and healthy, age, weight and height-matched 20 women and 5 men were evaluated. Disease activity was assessed using a variety of variables including erythrocyte sedimentation rate and C-reactive protein, tender joint count, swollen joint count, and Disease Activity Score-28.

Results: The mean ages of patients group (32.60±7.18) and control group (31.70±8.23) were similar (p=0.573). When we determine at the thiol/disulphide homeostasis parameters in both groups, we can see the mean native thiol (p=0.004), and native thiol/total thiol (p=0.000) levels is lower in the RA group than the control group. The mean disulphide level (p=0.000) was higher in the RA group than control group. The multiple regression analysis of thiol/disulphide balance and other risk factors was performed. Low thiol levels and high disulphide levels in patients with RA were found to be independent of gender, age and body mass index.

Conclusion:  In this study we have shown that thiol/disulphide homeostasis may be used as a novel oxidative stress marker in patients with rheumatoid arthritis. Further studies are needed to confirm the pathophysiologic role of thiol/ disulphide homeostasis in rheumatoid arthritis


Disclosure: S. Haliloglu, None; C. bicer, None; M. Alisik, None; B. Ekinci, None; M. E. Budak, None; O. volkan, None; H. Uzkeser, None; A. Carlioglu, None.

To cite this abstract in AMA style:

Haliloglu S, bicer C, Alisik M, Ekinci B, Budak ME, volkan O, Uzkeser H, Carlioglu A. Can Thiol/Disulphide Is a Novel Marker in Rheumatoid Arthritis? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/can-thioldisulphide-is-a-novel-marker-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-thioldisulphide-is-a-novel-marker-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology